Enzolve Technologies, the NovaUCD-headquartered life sciences company, today announced the appointment of Stuart Cranmer as its new CEO to drive and accelerate international sales.   Enzolve Technologies, a University College Dublin biotechnology spin-out company, established in 2002, develops and manufactures specially-designed enzymes, using proprietary technologies, for applications in healthcare, fine chemical and life science markets.  

Stuart Cranmer, CEO, Enzolve Technologies

Stuart Cranmer has over 25 years of healthcare management experience. Prior to joining Enzolve he was General Manager of Allergy Standards, a world leader in the testing and certifying of consumer goods. He has also held senior management roles in global diagnostics companies such as Bio-Rad, Biotrin and DiaSorin. In addition he mentors life sciences companies for Enterprise Ireland.  

Stuart has joined Enzolve at an exciting time as it adds to its NeoScreenPak range of tests. Enzolve is developing these tests to screen newborn babies faster and easier than conventional methods for a variety of metabolic disorders. Last year Enzolve formally launched its first CE-marked diagnostic test in the NeoScreenPak range, which screens for PKU (phenylketonuria) in newborn babies. 

Stuart, a graduate of the University of Luton, initially trained in the UK’s National Health Service in clinical biochemistry where he developed particular interests in immunology and immunological methods. He is also a graduate of the Dublin Institute of Technology.  

ENDS

30 March 2010

For further information contact Micéal Whelan, NovaUCD, e: miceal.whelan@ucd.ie, t: +353 1 716 3712.

Editors Notes

Enzolve Technologies Ltd is a privately-owned biotechnology company established in 2002 by Dr Paul C. Engel and Dr Suren Aghajanian as a spin-out from UCD’s School of Biomolecular and Biomedical Science. Enzolve Technologies develops engineered enzymes and applies them in the healthcare and life sciences markets, especially in the area of newborn screening of babies for inborn errors of metabolism.  

NovaUCD is University College Dublin’s Innovation and Technology Transfer Centre.  NovaUCD is responsible for the commercialisation of intellectual property arising from UCD research and for the development of co-operation with the industry and business communities. NovaUCD as a purpose-built incubation centre also nurtures new technology and knowledge-intensive enterprises. Twenty-seven companies, including Enzolve Technologies, are currently located in NovaUCD. NovaUCD has been funded through a unique public-private partnership that includes AIB Bank, Arthur Cox, Deloitte, Enterprise Ireland, Ericsson, Goodbody Stockbrokers, UCD and Xilinx.